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Epithelial-Mesenchymal Transitions of Bile Duct Epithelial Cells 
in Primary Hepatolithiasis
The purpose of this study was to explore the role of epithelial-mesenchymal transition in 
the pathogenesis of hepatolithiasis. Thirty-one patients with primary hepatolithiasis were 
enrolled in this study. Expressions of E-cadherin, α-catenin, α-SMA, vimentin, S100A4, 
TGF-β1 and P-smad2/3 in hepatolithiasis bile duct epithelial cells were examined by 
immunohistochemistry staining. The results showed that the expressions of the epithelial 
markers E-cadherin and α-catenin were frequently lost in hepatolithiasis (32.3% and 25.9% 
of cases, respectively), while the mesenchymal markers vimentin, α-SMA and S100A4 were 
found to be present in hepatolithiasis (35.5%, 29.0%, and 32.3% of cases, respectively). The 
increased mesenchymal marker expression was correlated with decreased epithelial marker 
expression. The expressions of TGF-β1 and P-smad2/3 in hepatolithiasis were correlated 
with the expression of S100A4. These data indicate that TGF-β1-mediated epithelial-
mesenchymal transition might be involved in the formation of hepatolithiasis.
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INTRODUCTION 
Primary hepatolithiasis (HL), a condition marked by the pres-
ence of calculus in intrahepatic ducts, is a common disease in 
China, especially prevalent in the Eastern and Southern regions 
of China. Although HL is a benign disease, it is intractable and 
usually requires operative interventions due to frequent stone 
recurrences (1). Most importantly, this disease is associated with 
biliary cirrhosis, and even cholangiocarcinoma. Clinical and 
experimental studies demonstrated that hepatolithiasis is asso-
ciated with chronic inflammation of bile ducts, biliary fibrosis, 
biliary stricture, and bacterial infections (2, 3). However, the cel-
lular and molecular pathogenesis of hepatolithiasis remains 
elusive. Many previous studies have focused on the formation 
of stones, while little attention has been paid to the role of bile 
duct epithelial cells (BEC). 
  Epithelial-mesenchymal transition (EMT) is, by definition, a 
process whereby epithelial cells are converted to migratory mes-
enchymal cells. This process is characterized by a loss of cell po-
larity and acquired expression of mesenchymal components 
(4). EMT results in a dramatic remodeling of the cytoskeleton, 
which includes reduced expression of cell adhesion molecules 
(i.e., E-cadherin) and the transition of keratin-based cytoskele-
ton into vimentin-based cytoskeleton, thus leading to changes 
in cell morphology. It has been reported that EMT contributes 
to both renal fibrogenesis and the fibrogenetic processes of he-
patocirrhosis (5, 6). 
  It has been shown that pleiotropic cytokines, members of the 
transforming growth factor-β (TGF-β) family, are involved in 
multiple physiological and pathological processes, including 
cellular proliferation, adhesion, apoptosis, differentiation and 
immunoregulatory activities. TGF-β1 activates Smad signaling 
via its two cell surface receptors-TGF-β type I receptor (TβRI) 
and TGF-β type II receptor (TβRII), leading to Smad-mediated 
transcriptional regulation of target genes (7, 8). Recently, Rygiel 
et al. reported that bile duct epithelial cells underwent EMT dur-
ing chronic liver diseases, which was associated with TGF-β1 (9). 
  Based on the observations above, we supposed that mesen-
chymal transition of BECs also play a role in the development 
of primary hepatolithiasis. Therefore, this study aimed at explor-
ing whether intrahepatic biliary epithelial cells undergo EMT in 
hepatolithiasis, and the possible role of TGF-β1-Smad2/3 signal 
pathway in EMT in hepatolithiasis.
MATERIALS AND METHODS
Patients and samples
The hepatolithiasis tissue samples were obtained from the Insti-
tute of Hepatobiliary Surgery of Southwest Hospital, the Third 
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mittee of the Third Military Medical University (IRB approval 
ID: KY200803). Written informed consent was obtained from 
all patients. 
  During March 2008 and December 2008, a total of 31 surgi-
cally resected hepatolithiasis specimens from primary hepato-
lithiasis were collected at the two ends of the stones (9 cases of 
male, 22 cases of female, average age 47.6±11.4 yr). Of the 31 
cases of HL, 25 patients had a history of cholangitis. There were 
16 cases of left hepatic duct stones, including five cases accom-
panied with choledocholithiasis and one case accompanied 
with cholecystolithiasis. There were 8 cases of right hepatic duct 
stones, three cases were accompanied with choledocholithiasis. 
There were 7 cases of combined left and right HL, four cases were 
accompanied with comorbid choledocholithiasis and three cas-
es were accompanied with comorbid cholecystolithiasis. Nor-
mal surrounding tissues (paraffin embedded) of 18 cases of cav-
ernous hemangioma of the liver were used as the control.
  All patients with hepatolithiasis were pathologically diagnos–
ed and graded into three grades according to the distribution of 
stones and pathological changes as described previously (10). 
Briefly, Grade I (localized) was characterized by stones that were 
confined to the hepatic segments or hepatic bile ducts, with liver 
involvement and few pathological changes in bile ducts. Grade 
II (regional) was characterized by a regional distribution of stones 
in the intrahepatic bile ducts permeating into one or several he-
patic segments, combined with biliary duct stenosis and involve-
ment of hepatic atrophy. Grade III (diffuse type) was character-
ized with or without obvious hepatic parenchymal atrophy and 
fibrosis, combined with stenosis of the main hepatic ducts in 
diseased regions or as having extensive hepatic fibrosis and for-
mation of secondary biliary cirrhosis and portal hypertension, 
combined with the serious stenosis. Cholangiocarcinoma was 
excluded through pathological diagnosis.
Histopathological and Immunohistochemical (IHC) studies
All resected specimens were fixed in 4% paraformaldehyde, em-
bedded in paraffin and cut into 4-μm-thick sections. Before IHC 
staining, all sections were deparaffinized and heated in citrate 
buffer (10 mM/L citric acid, pH 6.0) in a microwave oven. After 
inactivation by exposure to 3% H2O2 for 10 min, which blocks 
the activity of endogenous peroxidases, the sections were incu-
bated with blocking serum at room temperature for 10 min. IHC 
staining was carried out with the primary antibodies anti-α-SMA 
(Dako, Glostrup, Denmark), anti-E-cadherin, anti-α-catenin, 
anti-vimentin, anti-S100A4, anti-TGF-β1, and anti-P-smad2/3 
(Santa Cruz, CA, USA). After incubation with secondary anti-
bodies, expressions of these markers in cells were detected with 
diaminobenzidine (DAB; Sigma, St. Louis, MO, USA) by enhan–
cement with a SABC kit (ZSGB-BIO, Beijing, China). Tissue sec-
tions stained without primary antibody served as a negative 
control. The slides were then counterstained with hematoxylin. 
Images were captured by Baumer digital camera with an Olym-
pus BX51 microscopy (Olympus, Tokyo, Japan). 
  Brown granular staining was considered to be a positive sig-
nal for the IHC assay. On each slice, BECs of at least 10 portal 
areas were counted and the positive rates were calculated man-
ually. The portal areas were chosen randomly, without consid-
ering the magnitude of bile duct. Immunostaining of E-cadherin 
and α-catenin was evaluated according to the method described 
previously (11). N-cadherin expression was considered to be nor-
mal if >90% of BECs exhibited a staining pattern similar to that 
seen in normal epithelial cells; sections with <90% of BECs sta–
ined were classified as having a “lost pattern” . The intensity of 
vimentin, α-SMA and S100A4 was determined in the same way 
as that of N-cadherin staining (12). Briefly, the samples were di-
vided into two groups based on the intensity of staining these 
mesenchymal markers in BECs: a positive group in which >20% 
of BECs were stained positively and a negative group in which 
<20% of BECs were stained positively.
Statistical analysis
Measurement data was compared with t test, and chi-squared 
test was performed to compare numerical data. A P value <0.05 
was considered statistically significant. All calculations were per-
formed on a personal computer using the statistical software 
package SPSS 13.0 (Statistical Package for the Social Sciences; 
SPSS, Munich, Germany).
RESULTS
According to the clinical information and histopathologic chan–
ge, 31 cases were classified as grade I (n=10 cases), grade II (n=8 
cases) and grade III (n=13 cases). All sections of HL showed dif-
ferent degree of infiltration of inflammatory cells in portal areas, 
fibrous tissue hyperplasia, biliary dilatation, and necrosis (Fig. 1).
  E-cadherin and α-catenin were expressed in the plasma mem-
brane as continuous linear staining and the cytoplasm. The E-
cadherin- and α-catenin-positive BECs in HL were less than 
that in control group (P=0.001, and P=0.012, respectively). In 
HL group, the cases with less than 90% BECs expressing E-cad-
herin accounted for 32.3%, significantly higher than that in con-
trol group (P=0.038) (Fig. 2). Conversely, vimentin-, α-SMA- and 
S100A4-positive BECs in HL were significantly more than that 
in control group (Table 1). In HL group, the cases with more than 
20% BECs expressing vimentin, α-SMA and S100A4 accounted 
for 35.5%, 29.0% and 32.3%, respectively, significantly higher 
than those in control group (P=0.036, P=0.018, and P=0.008,) 
(Fig. 2C-F). There was very little expression of these three mes-
enchymal proteins in the control group. Collectively, there was 
increased expression of mesenchymal markers and reduced 
expression of epithelial markers in HLBECs, which indicated 
that EMT might be involved in the development to HL.Zhao L, et al.  •  Epithelial-Mesenchymal Transitions of Bile Duct Epithelial Cells in Primary Hepatolithiasis
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Fig. 2. Immunohistochemical assessment of epithelial and mesenchymal markers. 
Expressions of the epithelial markers (A) E-cadherin and (B) α-catenin in primary 
hepatolithiasis. Some BECs lost expression of epithelial markers (arrows). Expressions 
of mesenchymal markers (C) Vimentin, (D) α-SMA and (E) S100A4 in the liver bile 
ducts in hepatolithiasis. Note the brown staining of the markers lining the plasma 
membrane and in the cytoplasm (arrows). In normal liver tissue, S100A4 is neganative 
(F). Magnification ×400.
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  Although the expressions of TGF-β1 and P-smad2/3 were not 
significantly different from that in the control tissues (38.7% vs. 
16.7% and 48.4% vs. 22.2%, respectively, P>0.05), the expressions 
of TGF-β1 and P-smad2/3 were parallel with the expressions of the 
mesenchymal markers (vimentin, α-SMA and S100A4) (Fig. 3). 
Positive relationship between TGF-β1 or P-smad2/3 and S100A4 
was observed (r=0.737, and r=0.658, respectively). These results 
indicate that TGF-β1 may play an important role in EMT in the 
development of HL.
  The relationship between the expression of the epithelial and 
mesenchymal markers and clinical characteristics is shown in 
Table 2. The expression of S100A4 was associated with the clini-
cal grading of HL. Although no statistical relationship between 
Fig. 1. Histopathological assessment of HL. Histopathological assessment (hematoxylin-eosin staining) of samples from (A) control group and (B) primary hepatolithiasis, 
abnormalities in which include infiltrating inflammatory cells in portal areas, fibrous tissue hyperplasia, biliary dilatation, and necrosis. Magnification ×200.
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Table 1. Differences in the expressions of epithelial markers and mesenchymal mar–
kers in primary hepatolithiasis and control groups
Proteins Group
Positive BEC/total 
BEC (%)
P
E-cadherin Control
HL BEC
94.57±3.03
89.51±3.97
0.001
α-Catenin Control
HL BEC 
93.58±4.98
89.26±5.88
0.012
Vimentin Control
HL BEC 
  6.27±6.20
  18.13±18.09
0.002
α-SMA Control
HL BEC
  5.70±3.93
  17.50±16.81
0.001
S100A4 Control
HL BEC
  4.40±4.64
  18.4±5.54
0.001
HL, hepatolithiasis; α-SMA, α-smooth muscle actin; BEC, biliary epithelial cell; EMT, 
epithelial-mesenchymal transition.Zhao L, et al.  •  Epithelial-Mesenchymal Transitions of Bile Duct Epithelial Cells in Primary Hepatolithiasis
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the other markers and clinical grading of HL was observed, there 
was a tendency of negative correlation between clinical severity 
and the expression of E-cadherin and α-catenin (P=0.075 and 
P=0.052), and a tendency of positive correlation between clini-
cal severity and vimentin and α-SMA (P=0.078, P=0.085). 
  A number of recent studies have suggested that loss of epithe-
lial markers and gain of mesenchymal markers defines the pro-
cess of EMT (13). The statistical analysis suggested that the pres-
ence of mesenchymal markers was associated with the lost of 
epithelial markers in HL (Table 3), which further supports the 
existence of EMT.
DISCUSSION
Primary hepatolithiasis is a common and benign disease in Chi-
na, and the clinical progression of this disease may result in bile 
duct stricture, liver parenchyma atrophy and chronic ﬁbrosis due 
to repeated pyogenic cholangitis (14). Moreover, cholangiocar-
cinoma is found in approximately 5-10% of patients with hepa-
tolithiasis (2). Therefore, it is essential to explore the cellular and 
molecular mechanisms that mediate the pathogenesis of hepa-
tolithiasis.
  EMT, first appreciated as a developmental event in early em-
Table 2. Correlation between clinical stage and the expressions of epithelial markers (E-cadherin and α-catenin) and mesenchymal markers (vimentin and α-SMA) in HLBECs
Clinical grade* No.
E-cadherin
P
α-Catenin
P
Vimentin
P
α-SMA
P
S100A4
P Positive  
BEC (%)
Positive  
BEC (%)
Positive 
BEC (%)
Positive 
BEC (%)
Positive 
BEC (%)
1 10 91.42±1.68 91.39±1.47 12.97±14.57 14.26±10.98 14.58±2.58
2   8 90.03±4.05 0.075 91.44±5.25 0.052 10.77±18.96 0.078 9.38±16.38 0.085 16.79±4.0 0.001
3 13 87.72±4.59 86.29±7.24 26.60±17.68 25.01±18.59 22.33±5.67
*See Methods for details.
Table 3. Correlation between loss of epithelial markers (E-cadherin and α-catenin) and expression of mesenchymal markers (vimentin and α-SMA) in HLBECs
Markers No.
vimentin
P
α-SMA
P
S100A4
P
Positive BEC (%) Positive BEC (%) Positive BEC (%)
E-cadherin
   >90%
   <90%
21
10
10.57±10.09
34.01±20.31
0.005 10.77±9.37
  31.65±20.47
0.011 16.25±4.17
22.92±5.47
0.004
α-Catenin
   >90%
   <90%
23
  8
  9.86±10.68
41.89±13.19
0.001 10.24±9.13
  38.40±16.60
0.002 16.09±3.76
23.25±5.68
0.001
Fig. 3. Immunohistochemical assessment of TGF-β1 and P-smad2/3. (A) TGF-β1 expressed in the cytoplasm and on the plasma membrane of bile duct epithelial cells in 
hepatolithiasis, and (B) P-smad2/3 accumulated in the nucleus of bile duct epithelial cells in hepatolithiasis. Magnification ×400. 
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bryonic morphogenesis, is a process whereby epithelial cells lose 
polarity and cell-cell contacts and acquire the ability to express 
mesenchymal components and manifest a migratory phenotype 
(13, 15). Studies have revealed that the morphological transition 
from an epithelial to a fibroblastic appearance is accompanied 
by a gain of mesenchymal cell markers (fibronectin, vimentin, 
smooth muscle, actin, and N-cadherin) and a loss of epithelial 
markers (E-cadherin, and α- and β-catenin) (16). EMT-like chang-
es are thought to be involved in many pathological processes, 
such as renal fibrosis (17), epithelial hyperplasia and tumor me-
tastasis (13). Moreover, the studies suggest that EMT plays a crit-
ical role in liver and biliary diseases. Consistent with these stud-
ies, our results showed that the bile duct epithelial cells in HL 
underwent a lost of epithelial markers and acquirement of mes-
enchymal markers, suggesting the presence of EMT. Meanwhile, 
this study indicates that the expression of epithelial and mesen-
chymal markers is associated with clinical severity, which show–
ed that local inflammatory factors may be involved in the de-
velopment of EMT while leading tissue injury.
  Of the many factors that regulate EMT, TGF-β1 is regarded as 
a key cytokine that induces EMT through Smads and Smads-in-
dependent pathways (13, 16). Treatment with TGF-β1 was suf-
ficient to induce EMT in BECs, as demonstrated by loss of E-cad-
herin staining and gain of S100A4, Smad2/3, and α-SMA (18). In 
our study, there was no significant difference between TGF-β 
expressions of HL and control group. However, we find that the 
expression of TGF-β and Smad2/3 was associated with the ex-
pression of mesenchymal markers, especially S100A4. Our re-
sults were compatible with Rygiel’s report that TGF-β1 was as-
sociated with EMT of bile duct epithelial cells during chronic 
liver diseases (9). However, whether EMT is caused by the com-
bination of HL and concomitant inflammation or whether EMT 
induces bile duct stricture and stones needs further study. In the 
future, we plan to analyze the role of EMT in biliary infections 
through simulating infections via the administration of inflam-
matory cytokines to intrahepatic biliary epithelial cells (IBECs) 
in vitro. The interactions between BECs and infiltrating T cells 
will be considered as well.
  In conclusion, in biliary epithelial cells from patients with pri-
mary hepatolithiasis, we found the loss of epithelial markers and 
the acquirement of mesenchymal markers following stimulation 
of the TGF-β1/smad2/3 signaling pathway. Our study indicates 
that TGF-β1-mediated EMT might be involved in the pathogen-
esis of hepatolithiasis.
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